Venetoclax

證據等級: L5

預測適應症: 10 個

Venetoclax (DB11581): A BCL-2 Inhibitor with a Multi-Indication Prediction Portfolio

One-Sentence Summary

Venetoclax is a selective BCL-2 inhibitor; this evidence pack does not contain confirmed original-indication or TFDA label data for the Taiwan market (drug is currently not marketed in Taiwan, 0 licenses), so the “from → to” framing used for single-indication reports does not apply cleanly here. Instead, TxGNN generated 10 candidate indications for this drug, with wildly varying evidence quality — ranging from a well-supported, guideline-relevant signal for acute myeloid leukemia (AML) (50+ trials, 20+ publications, Phase 3 RCTs) down to a single unsupported prediction for malignant spiradenoma (zero trials, zero literature). Because of this spread, the report below evaluates the portfolio as a whole and flags data-quality concerns (including a likely ontology-mislabeling issue in the Hodgkin lymphoma entry) rather than presenting one indication as “the” prediction.

Quick Overview

Item	Content
Original Indication	Not available — TFDA label and original indication data are a Blocking data gap (DG001); background pharmacology indicates venetoclax is an internationally used BCL-2 inhibitor (CLL/SLL, AML), but this is not confirmed in-dataset
Predicted New Indication	10 candidates (multi-indication pack); top-ranked by TxGNN score: CLL/SLL with IGHV somatic hypermutation — but the most clinically actionable is myeloid leukemia (AML) (Rank 4)
TxGNN Prediction Score	Rank 1: 99.55% · Rank 4 (AML): 99.47% · range across portfolio: 99.08%–99.55%
Evidence Level	Highly variable: L1 (AML) down to L5 (malignant spiradenoma) — see portfolio table below
Taiwan Market Status	未上市 (Not Marketed)
Number of Licenses	0
Recommended Decision	Indication-specific — Proceed with Guardrails (AML); Research Question (CML, follicular lymphoma, CLL/SLL subtypes); Hold (Hodgkin lymphoma, metastatic neoplasm, Ewing sarcoma, malignant spiradenoma)

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data from DrugBank is marked as a data gap (DG002) in this pack. Based on the mechanistic rationale embedded in the individual predictions, venetoclax is a selective, orally bioavailable BCL-2 antagonist that restores apoptosis in malignant cells that depend on BCL-2 overexpression for survival — the “BH3-mimetic” mechanism. This is consistent across nearly every candidate in this portfolio, since BCL-2 dependency is a shared vulnerability across many B-cell and myeloid malignancies.

Portfolio Overview (all 10 candidates):

Rank	Predicted Indication	Score	Evidence Level	Decision Stage	Recommendation	Key Note
4	Myeloid leukemia (AML)	99.47%	L1	S3	Proceed with Guardrails	Core, already-validated venetoclax use (FDA-approved combo with azacitidine/LDAC); strongest evidence in the pack
5	Chronic myelogenous leukemia, BCR-ABL1+ (CML)	99.36%	L2	S2	Research Question	Stem-cell-eradication hypothesis on top of TKI therapy; Phase 2 trials only
7	Follicular lymphoma	99.15%	L2	S2	Research Question	t(14;18)-driven BCL-2 overexpression is a strong mechanistic fit; multiple Phase 1/2 combos, no Phase 3 yet
1	CLL/SLL (IGHV-mutated subtype)	99.55%	L4	S1	Research Question	Mechanistically sound (CLL is a core BCL-2-dependent malignancy) but zero trials/literature for this specific IGHV subtype in the pack
2	Pre-germinal-center CLL/SLL	99.55%	L4	S1	Research Question	Same as above; only supporting literature is a descriptive BCR-biology review, not efficacy data
10	AML with t(8;21) translocation	99.08%	L4	S1	Research Question	Reasonable extrapolation from the AML entry above, but zero trials/literature specific to this cytogenetic subtype
6	Ewing sarcoma	99.21%	L4	S0	Hold	Preclinical rationale only (BCL-2/BCL-XL dependency in some cell lines); zero clinical trials
3	Hodgkin lymphoma	99.51%	L4	S0	Hold	⚠️ Likely ontology mislabeling — all 50 trials and 20 papers listed actually describe non-Hodgkin lymphoma (CLL/MCL/DLBCL/FL); no genuine classical Hodgkin lymphoma evidence is present
8	Metastatic neoplasm	99.14%	L4	S0	Hold	Non-specific KG node; cited evidence spans breast cancer, AML, ALL, neuroblastoma — not an actionable single indication
9	Malignant spiradenoma	99.12%	L5	S0	Hold	Zero trials, zero literature; prediction-only with no biological or clinical corroboration

Interpretation: The pack’s own rationale text for AML explicitly notes this is “not a hypothesis” — venetoclax + azacitidine/LDAC is already a validated, guideline-endorsed first-line AML regimen internationally. Since Taiwan market status shows “not marketed” and original indication is a data gap, this most plausibly reflects a jurisdictional gap (drug not yet registered locally) rather than a genuinely novel biological hypothesis. In contrast, several other entries (Hodgkin lymphoma, metastatic neoplasm, malignant spiradenoma) look like knowledge-graph noise — either mislabeled evidence linkage or prediction with no supporting signal at all — and should not be advanced without independent verification.

Clinical Trial Evidence (Lead Candidate: Myeloid Leukemia / AML)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03573024	Phase 2	Active, not recruiting	36	Venetoclax + azacitidine in newly diagnosed non-elderly (18–59) AML
NCT07486479	Phase 3	Not yet recruiting	204	RCT: venetoclax + azacitidine + mitoxantrone liposome vs. idarubicin + cytarabine (“3+7”) in newly diagnosed AML
NCT06046313	Phase 2	Recruiting	120	Prolonged ultra-low-dose decitabine + venetoclax in elderly/high-risk AML and MDS
NCT06782542	Phase 2	Recruiting	16	Olutasidenib + venetoclax + azacitidine in IDH1-mutated newly diagnosed AML
NCT05520567	Phase 1/2	Active, not recruiting	70	Gilteritinib + venetoclax + azacitidine in FLT3-mutated AML unfit for intensive induction
NCT05317494	N/A (real-world)	Recruiting	100	Non-interventional study of venetoclax as first-line therapy in intensive-chemo-ineligible AML (Greece)
NCT04824924	Phase 2	Unknown	100	Venetoclax + low-dose HHT + G-CSF + azacitidine in elderly unfit newly diagnosed AML
NCT03844815	Phase 1	Active, not recruiting	26	Venetoclax + 10-day decitabine regimen safety/tolerability in AML

Literature Evidence (Lead Candidate: AML)

PMID	Year	Type	Journal	Key Findings
34329576	2021	Cohort, single-arm Phase 2	The Lancet Haematology	Venetoclax + cladribine/idarubicin/cytarabine (CLIA) in newly diagnosed AML/high-risk MDS, patients ≤65 years
35046058	2022	Cohort	Clinical Cancer Research	Venetoclax + azacitidine efficacy/safety in treatment-naïve IDH1/2-mutant AML
37599456	2024	Network meta-analysis	Journal of Chemotherapy	Indirect comparison: venetoclax+azacitidine vs. ivosidenib/enasidenib in unfit IDH1/2-mutant AML; VEN-AZA showed superior OS
39303729	2024	Single-arm Phase 2	The Lancet Haematology	Decitabine + venetoclax + ponatinib in advanced-phase Ph+ CML and Ph+ AML
37925935	2023	Review	Biomedicine & Pharmacotherapy	Summary of venetoclax mono/combination efficacy across AML preclinical and clinical studies
31203996	2019	Review	Best Practice & Research Clinical Haematology	Overview of venetoclax-based therapies within the broader new-drug landscape for AML
32031033	2020	Review	Leukemia & Lymphoma	Venetoclax + HMA/LDAC established as new frontline standard of care in older/unfit AML
39246164	2024	Review	Expert Review of Hematology	Relapse and resistance patterns after venetoclax-based AML therapy; second-line strategies

Taiwan Market Information

Venetoclax currently has no marketing authorization recorded in Taiwan (market status: 未上市 / Not Marketed; 0 licenses on file). No license table can be generated from this dataset.

Cytotoxicity

Venetoclax’s indications across this portfolio are predominantly hematologic malignancies (leukemia, lymphoma), and it is a well-established antineoplastic/targeted oncology agent, so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy — selective BCL-2 (BH3-mimetic) inhibitor; not a conventional cytotoxic chemotherapeutic
Myelosuppression Risk	High — neutropenia is a common, sometimes dose-limiting toxicity, particularly in combination regimens (e.g., + azacitidine/decitabine); thrombocytopenia also reported
Emetogenicity Classification	Low
Monitoring Items	CBC with differential (regular); tumor lysis syndrome labs during initiation/dose ramp-up (potassium, phosphate, calcium, uric acid, creatinine); renal and hepatic function
Handling Protection	Yes — despite being an oral targeted agent, venetoclax is classified as a hazardous antineoplastic drug and requires handling per institutional cytotoxic/hazardous drug protocols, especially given tumor lysis syndrome risk requiring structured dose ramp-up

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are not available in this dataset — TFDA label retrieval is a Blocking data gap, DG001.)

Conclusion and Next Steps

Decision: Indication-Specific — Proceed with Guardrails (AML only); Hold on the majority of remaining candidates

Rationale:

The AML candidate (Rank 4) is backed by L1 evidence, including a Phase 3 RCT and an established, internationally used venetoclax + hypomethylating-agent regimen — this is the only candidate in the portfolio warranting active progression.
CML and follicular lymphoma (Ranks 5 and 7) have plausible mechanistic rationale and multiple Phase 1/2 trials but no Phase 3 confirmation — appropriate to track as research questions, not to advance to development.
The Hodgkin lymphoma (Rank 3), metastatic neoplasm (Rank 8), and malignant spiradenoma (Rank 9) entries show serious data-quality issues (apparent ontology mislabeling, non-specific KG nodes, or zero supporting evidence) and should not be treated as genuine repurposing signals without manual re-validation of the underlying knowledge graph edges.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/international label data — safety warnings, contraindications, DDI — before any S1 safety pre-assessment can begin.
Resolve DG002 (High): confirm venetoclax’s original indication and MOA via DrugBank API to correctly frame this as a market-entry/registration gap rather than a purely novel repurposing hypothesis.
Re-audit the Hodgkin lymphoma prediction’s KG edges — the evidence attached to it does not match the labeled disease and should be corrected or removed upstream.
If pursuing the AML pathway for the Taiwan market, this is functionally a new drug registration question (given 0 existing licenses), not a repurposing question — recommend routing to regulatory/registration workflow rather than repurposing evaluation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.